scholarly journals Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting

Liver Cancer ◽  
2017 ◽  
Vol 6 (4) ◽  
pp. 264-274 ◽  
Author(s):  
Zhao-Chong Zeng ◽  
Jinsil Seong ◽  
Sang Min Yoon ◽  
Jason Chia-Hsien Cheng ◽  
Ka-On Lam ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Liver Cancer ◽  
Stereotactic Body Radiation Therapy ◽  
Primary Liver Cancer ◽  
Asia Pacific ◽  
Stereotactic Body Radiation ◽  
Expert Meeting

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

2020 ◽  
Vol 04 (02) ◽  
pp. 187-194
Author(s):  
Shauna R. Campbell ◽  
Timothy D. Smile ◽  
Sarah M.C. Sittenfeld ◽  
Kevin L. Stephans
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Primary Liver Cancer ◽  
Effective Treatment Option ◽  
Stereotactic Body Radiation ◽  
Common Cancer ◽  
Clinical Presentations ◽  
Liver Cancers ◽  
Bridging To Transplant

AbstractPrimary liver cancer is the seventh most common cancer worldwide and is the second leading cause of cancer-related death. Hepatocellular carcinoma (HCC) accounts for three-quarters of primary liver cancers and less than a third of patients present with curable disease. Liver-directed therapy is essential for the treatment of patients with unresectable HCC and the advancement of stereotactic body radiation therapy (SBRT) has made radiation a safe and effective treatment option in a range of clinical presentations. In this review, we discuss the technical aspects of SBRT and the general approach to treatment of HCC. We explore the use of SBRT for bridging to transplant, downstaging, and the treatment of large tumors and portal vein tumor thrombus. Although there is limited high-quality randomized data, we review the evidence comparing SBRT with other liver-directed therapies and explore areas for future investigation.

scholarly journals Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials

Liver Cancer ◽  
2016 ◽  
Vol 5 (3) ◽  
pp. 162-174 ◽  
Author(s):  
Hee Chul Park ◽  
Jeong Il Yu ◽  
Jason Chia-Hsien Cheng ◽  
Zhao Chong Zeng ◽  
Ji Hong Hong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Trials ◽  
Liver Cancer ◽  
Current Practice ◽  
Primary Liver Cancer ◽  
Asia Pacific ◽  
Expert Meeting

Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer

2017 ◽  
Vol 7 (3) ◽  
pp. 173-182 ◽  
Author(s):  
Diego A.S. Toesca ◽  
Evan C. Osmundson ◽  
Rie von Eyben ◽  
Jenny L. Shaffer ◽  
Albert C. Koong ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Liver Cancer ◽  
Stereotactic Body Radiation Therapy ◽  
Primary Liver Cancer ◽  
Hepatic Function ◽  
Stereotactic Body Radiation

scholarly journals Comparison of stereotactic body radiation therapy versus fractionated radiation therapy for primary liver cancer with portal vein tumor thrombus

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Sujing Zhang ◽  
Li He ◽  
Changwen Bo ◽  
Shufang Yang ◽  
Yonghui An ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Liver Cancer ◽  
Portal Vein ◽  
Clinical Outcomes ◽  
Tumor Thrombus ◽  
Stereotactic Body Radiation Therapy ◽  
Primary Liver Cancer ◽  
Stereotactic Body Radiation ◽  
Fractionated Radiation Therapy ◽  
Fractionated Radiation

Abstract Background To compare the clinical outcomes of stereotactic body radiation therapy (SBRT) and fractionated radiation therapy (FRT) for primary liver cancer with portal vein tumor thrombus (PVTT). Methods This retrospective study included 36 patients who underwent SBRT and 36 patients who underwent FRT from August 2016 to June 2018. Patients were evaluated for short-term efficacy, long-term efficacy, AEs, and quality of life before and after treatment. Results With a median follow-up of 28.8 months (26–36 months), 27 patients survived in the SBRT group while 19 patients survived in the FRT group. The survival rate in the SBRT group was statistically higher than that of the FRT group after 6 months (80.56% vs. 58.33%; P = 0.041), 12 months (77.78% vs. 55.56%; P = 0.046) and 24 months 75.00% vs. 52.78%; P = 0.049). The median whole survival time of the SBRT group was 13.3 months (95% CI 12.83–13.97), which was statistically longer than 9.8 months in the FRT group (95% CI 8.83–10.97, P < 0.05) based on the Kaplan–Meier method. The SBRT group had better survival quality and fewer adverse events than the FRT group. Conclusion SBRT had better clinical outcomes than FRT for primary liver cancer with PVTT.

scholarly journals Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)

Liver Cancer ◽  
2015 ◽  
Vol 4 (4) ◽  
pp. 215-227 ◽  
Author(s):  
Bang-Bin Chen ◽  
Takamichi Murakami ◽  
Tiffany Ting-Fang Shih ◽  
Michiie Sakamoto ◽  
Osamu Matsui ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Asia Pacific ◽  
Imaging Diagnosis ◽  
Expert Meeting
Sign in / Sign up

Export Citation Format

Share Document